Revenue Breakdown
Composition ()
No data
Revenue Streams
Dynavax Technologies Corp (DVAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HEPLISAV-B, accounting for 94.8% of total sales, equivalent to $89.95M. Another important revenue stream is Other revenue. Understanding this composition is critical for investors evaluating how DVAX navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Dynavax Technologies Corp maintains a gross margin of 84.82%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.42%, while the net margin is 28.38%. These profitability ratios, combined with a Return on Equity (ROE) of -7.14%, provide a clear picture of how effectively DVAX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, DVAX competes directly with industry leaders such as ANIP and IMCR. With a market capitalization of $1.76B, it holds a significant position in the sector. When comparing efficiency, DVAX's gross margin of 84.82% stands against ANIP's 49.07% and IMCR's 99.51%. Such benchmarking helps identify whether Dynavax Technologies Corp is trading at a premium or discount relative to its financial performance.
